|Bid||0.00 x 800|
|Ask||0.00 x 21500|
|Day's Range||42.03 - 42.79|
|52 Week Range||33.20 - 46.47|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||10.64|
|Forward Dividend & Yield||1.44 (3.40%)|
|1y Target Est||N/A|
TRENTON, N.J. (AP) — A woman who said she was fired by a major pharmaceutical company because of her religious beliefs won a court victory Wednesday when a state appeals panel ruled that she didn't agree in an online form to waive her rights to sue.
Why Ligand Pharmaceuticals Tanked 25%Ligand Pharmaceuticals Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day. At the same time, other pharmaceutical companies Amarin
# Pfizer Inc ### NYSE:PFE View full report here! ## Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.64 billion over the last one-month into ETFs that hold PFE are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.
Why Amarin Is Soaring in First Half of JanuaryStock price hikeOn January 11, Amarin (AMRN) closed at $18.00, which is 1.91% lower than its previous closing price. However, on January 10, 2019, the company closed at $18.35, almost 22% higher than its
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.
Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.
House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Shares of cardiovascular health sciences company Amarin (NASDAQ:AMRN) surged 22% on Thursday. That continues an amazing ride for the maker of Vascepa, an Omega-3 fatty acids treatment to fight very high triglycerides. Amarin stock has soared from $3 in September to as high as $23 following its decisive REDUCE-IT study results. These results showed that Amarin's formulation of Omega-3 oils performs superiorly to other generic options. After years of criticism, Amarin demonstrated that it isn't "just another fish oil pill" as the bears had always retorted. Since the trial results, Amarin stock has remained highly volatile. Yes, it's clear Amarin has a viable commercial product on their hands now, but how many doctors will start prescribing it? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks the Smart Money Is Piling Into Can Amarin make it as a standalone operation or does it need a larger commercial backer? All these questions came to a head on Thursday when rumors broke that Pfizer (NYSE:PFE) or perhaps AstraZeneca (NYSE:AZN) was going to acquire Amarin outright. Amarin stock soared. ### Pfizer Buying Amarin? Probably Not Biotech journalist and Twitter heavyweight Adam Feuerstein weighed in on the Pfizer rumors, tweeting: "Help me with the logic here: $AMRN CEO John Thero just spent 4 days in [San Francisco] meeting face to face with investors while ALSO negotiating a $PFE takeout? People, please…" It's not uncommon for biotech management teams to pull out of conferences when they are about to be acquired. Particularly if Amarin already knew that Pfizer or someone else would bid for the company, why bother with in-person investor relations? There'd be more important business to attend to. Also, it's worth noting that Pfizer's comments at that same biotech conference didn't indicate that a deal is coming soon. Pfizer's CEO Albert Bourla noted that the company greatly stepped up its share buyback in 2018. It did so, Bourla said, in order to be able to boost R&D spending without hitting earnings. Adding to that Bourla commented rather directly that: "In the years before we had an issue with growth, so we were looking to buy revenues now or soon because this is what was lacking. Right now we are not in this situation. Right now we are in a situation that our R&D is very productive and I feel that mostly R&D type of deals is what we need to enhance even further our pipeline, given that we have higher confidence in our capabilities to do it, given that now we have very good focus on R&D." Pfizer's CEO stated it clearly: they don't need to acquire more drugs to obtain growth. The R&D pipeline is stuffed. Pfizer is unlikely to want to drop $8 billion or more to acquire Amarin at this time. ### Amarin: Short-Term Struggles A lot of Amarin stock bulls expected shares to fly up toward $30 in the immediate wake of the shockingly good REDUCE-IT trial data. Analysts have pegged future peak annual sales estimates for Vascepa at $2 billion to $4 billion sometime in the 2020s. Given Amarin's healthy patent position on the drug, this has the makings of being a blockbuster therapeutic. There's still the hitch that the company needs to convince the FDA to expand its marketing label for the drug later this year. However, given the strong data, this shouldn't be too much of an issue. For now, however, Amarin is still experiencing relatively soft sales. Amarin released guidance suggested that it will sell just $350 million of Vascepa in 2019. That was well short of the market's expectations. So far, since the REDUCE-IT data came out, Amarin has seen a decent bump in its weekly prescriptions. They're up from 11,000 pre-data release to 15,000 now. That's solid progress. Still, it's clear that without much more marketing and/or a wider label approval from the FDA, it will take awhile for Amarin to gain serious sales traction. ### Amarin Stock Takeaway That said, Amarin finds itself in a decent position nonetheless. It had $249 million in cash as of the latest report, suggesting that it has time to ramp up its sales operations as a separate company. Amarin lost $98 million on $205 million in revenues last year, suggesting it isn't especially close to profitability. Analysts forecast a much smaller, but still negative, net income figure for this year as well. Regardless, with that cash position, Amarin isn't desperate to find a suitor and can wait for an attractive offer. For now, I see AMRN as a solid trading stock. When there are short-term rips, such as the 22% pop on the Pfizer rumors, it is a good time to take profits. When the stock dips, say on weaker than expected earnings or prescription fills data, you can buy back in at a better price. In the short-term, I consider it highly unlikely that Pfizer or someone else like AztraZeneca is about to purchase Amarin. The actions from both companies' management teams suggest that a deal is not imminent. As such, it makes sense to ring the register on AMRN stock following the recent move from $13.50 at the start of the year to $18 now. If you like the Amarin story, you will get another chance to buy back in at a cheaper price as there are no immediate catalysts to drive Amarin stock higher. At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post Sell Amarin Stock on the Recent Takeover Rumors Rally appeared first on InvestorPlace.
Fears of a gradually slowing global economy started emerging mid-2018, alongside U.S. tariffs on goods from Canada, Mexico, the EU and, of course, China. More recent concerns about anemic oil and commodity prices and rapidly contracting productivity in China have only added to the uncertainty. One useful tool for getting an idea of a company's ability to weather the fallout of events like this is debt to capital ratios against its valuation and cash flow statistics.
In chapter four of Sven Carlin's book, "Modern Value Investing: 25 Tools to Invest With a Margin of Safety in Today's Financial Environment," the author observed that almost a century had passed since Benjamin Graham laid out the foundational principles of value investing. Warning! GuruFocus has detected 7 Warning Signs with PFE. According to Carlin, investors should not be afraid to pay taxes.
Pfizer Inc's two new drug applications for tafamidis for the treatment of a fatal heart condition have been accepted for filing by the U.S. Food and Drug Administration, the company announced Monday. Pfizer submitted the NDAs based on two forms of the drug for treatment of transthyretin amyloid cardiomyopathy, a fatal condition where a transport protein in the blood misfolds and results in a build-up of amyloid fibrils in the heart, the company said. One of those forms, tafamidis meglumine, was granted priority review and has a July 2019 Prescription Drug User Fee Act target date for FDA review, the company said. A Phase 3 study of tafamidis meglumine met its primary endpoint, showing a significant reduction in mortality and frequency of cardiovascular-related hospitalizations over 30 months compared to placebo. Shares of Pfizer have fallen 1.8% in the year to date, while the S&P 500 has gained 3.5%.
Given the meltdown we've seen across the entire market over the past 16 weeks, many investors may be overlooking company-specific and industry-specific news. One of those pieces of news? That a swath of pharmaceutical stocks are raising their prices in the new year. Pharmaceutical stocks and biotech companies are interesting plays in any market, partly due to their secular business nature. Meaning that, recession or boom, consumers need treatment. Whether it's as large as open heart surgery or small as a Tylenol, we pay for healthcare when we need it. For as secular as the group can be though, it has been under tremendous volatility lately. With that in mind, almost 40 companies started of 2019 with a series of prices hikes. The average raise was roughly 6.3%. So who were these companies and how do we trade their stocks? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * InvestorPlace Roundup: The Hottest Stocks in the Market Today Let's look at a few of those pharmaceutical stocks. ### Allergan (AGN) Allergan (NYSE:AGN) is known for its vast drug and treatment portfolio. However, at the turn of the year, Allergan raised prices on 51 of its products. That's just over half of its portfolio. Of those 51 products, 27 of them saw an increase of 9.5%. The rest were bumped by 4.9%. All that said, Allergan makes the case that it's not a money-hungry cash grab. Rather, the company says it should not see any net gains as a result of the price hikes because it's providing higher rebates and discounts to its distributors. Allergan may say that, but investors sure wish it would help. Analysts expect sales to fall 1.7% this year and another 1.6% next year. On the earnings front, expectations call for a 90-basis-point gain this fiscal year before a 0.7% decline in 2019. Essentially, estimates call for flat earnings growth overall from fiscal 2017 through 2019. That's likely one factor for why the stock has gone from $195 in October to roughly $125 at its December lows. As AGN approaches the $145 to $150 level now, look to see if and where resistance comes into play. There's downtrend resistance at play, as well as the gap-fill up near $145. It would be encouraging to see the $140-ish level hold as support, but that doesn't leave much wiggle room for Allergan. ### Bristol-Myers (BMY) No one is talking about recent dividend payout from Bristol-Myers Squibb (NYSE:BMY), nor are they talking about its recent price increases. The company raised prices on its cancer drugs Opdivo and Yervoy by 1.5%, while lifting prices by 6% on its chemotherapy treatment Sprycel and its autoimmune disease drug Orencia. However, most investors are talking about the company's $74 billion cash and stock acquisition of Celgene (NASDAQ:CELG). BMY was hammered on the news at first, but rebounded by about 4% on Friday once investors were able to digest the news. Management expects the deal to close in the third quarter of 2019. Creating over $2 billion in synergies and boosting growth, BMY management is hoping the acquisition makes its stock more attractive to investors. At just 12 times forward earnings with 8.5% sales growth and 28% earnings growth this year, BMY already looks reasonable. Throw in its 3.5% dividend yield and its even more attractive. * Morgan Stanley: 7 Risky Stocks to Sell Now On the charts, it's clear that dips down to the upper $40s have been viewed as buying opportunities by investors over the last four years. ### Eli Lilly (LLY) Eli Lilly (NYSE:LLY) isn't exempt when it comes to drug price increases, as it raises prices for Jardiance, a treatment for type 2 diabetes, by 6%. Unlike some of its peers, Eli Lilly has been on absolute fire. Shares are up 35% year-over-year and about 60% from its February lows. Despite the rally, LLY still pays out a 2.2% dividend yield and trades at a somewhat reasonable 20.6 times this year's earnings. Despite the big breakout rally in July, LLY has modest growth expectations. Analysts expect 6.8% and 4% sales growth this year and next year, respectively. Further, estimates call for 30.4% earnings growth this year and 6.5% growth in 2019. Fueling the breakout during the summer? A strong second-quarter result and potential IPO for one of its businesses. However, some may feel that LLY stock has rallied too far, too fast and that it's no longer a worthy buy. According to the charts, that may be the case if LLY is unable to push higher and take out its recent highs near $120. If it can break that level, the rally can continue. If not, look to see if uptrend support holds (blue line). Should it fail, LLY could be heading for a retest of its 200-day moving average. ### Pfizer (PFE) Pfizer (NYSE:PFE) delayed various price hikes in 2018, but pushed through its increases at the start of the year. Not many companies have been as open as Allergan about confirming its specific price hikes, but Pfizer may need them to keep pace in 2019. That is to say, PFE was one of the best-performing stocks in the Dow Jones last year. After consolidating between $30 and $36 for most of the last five years, shares finally broke out around the same time Eli Lilly did. In fact, their charts look quite similar too. After a big breakout six months ago, PFE is having trouble pushing higher. Should it fail to get through the 50-day and short-term uptrend support (blue line) gives way, a test of the 200-day moving average could be in the cards. Should it fail as support, a test of $38 is likely in store. Above the 50-day and a rally to $46 is possible. * 10 Stocks You Can Set and Forget (Even In This Market) Investors not worried about the charts will key in on Pfizer's 3.4% dividend yield and its valuation of 14 times this year's earnings. Although remember that 2018's 13.2% earnings growth is expected to slow to just 2.7% in 2019. ### Biogen (BIIB) Biogen (NASDAQ:BIIB) was also on the list of price increases for 2019. The company increased prices on its multiple sclerosis medications Tecfidera by 6%, Plegridy by 2% and Tysabri by 3.5%. Like other biotech stocks, Biogen has been volatile and struggling. Nowhere is this more evident than on the charts. Shares went from $370 in February to $250 in a matter of months, then hit nearly $400 per share in late July. Now near $330, BIIB bulls are near a make-or-break point. The stock has put in a series of lower highs (blue circles) since that big rally in July. Currently, both the 50-day and the 200-day moving averages rest at about $313. Investors who believe BIIB is attractive -- trading at about 12 times forward earnings with expectations to grow sales and earnings 2.5% and 8.5% in 2019, respectively -- will want to see it hold above these two marks. Should it fail, Biogen could quickly head to the bottom of its recent channel, somewhere in the $270 range. On the plus side though, if shares push higher and can close above $340, BIIB may be starting a new uptrend. ### Teva (TEVA) While Warren Buffett's Berkshire Hathaway (NYSE:BRK.B, NYSE:BRK.A) holds a $750 million stake in Teva Pharmaceuticals (NYSE:TEVA), it's far from his largest holding. Big or small, the Oracle has to be disappointed with the stock's recent action, falling from $24 in November to less than $15 at its lows last month. Now up over $17, bulls are hoping Teva stock can continue higher. Will it? Like the others on this list, Teva also raised prices on some of its drugs this year, although the specifics are not well known. So far the name has done well this year, though granted, were just a few sessions into 2019. In any regard, Teva is bumping into the backside of prior downtrend support (blue line). Should this level act as resistance, bulls will want $16.75 to act as support. If not, the recent lows are in play. Over resistance and the $19 to $20 level is on the table. * The 7 Best Stocks in the Entrepreneur Index While the stock trades at less than 7 times this year's earnings, keep in mind that growth has been tough. Sales are forecast to fall 15.8% this year, while analysts expect earnings to contract by 27%. In 2019, the slowdown decelerates, but analysts are still calling for a 4.8% reduction in revenue and a 3% fall in earnings. ### Insys Therapeutics (INSY) Though it is much smaller than most of the names on this list, Insys Therapeutics (NASDAQ:INSY) is joining them in raising prices -- in this case, on its pain-relief medication Subsys. INSY has a market cap of just $350 million. The move is probably necessary, given that sales are forecast to fall about 40.5% this year and another 5% in 2019. It doesn't help that INSY doesn't turn a profit, although its lack of debt is encouraging. Given the selloff we've seen in the stock market since the start of Q4 2018, it's no surprise that investors have cut INSY very little slack. Shares came into Q4 near $10, but are now clinging to the $4.25 level. To say it's been a rough ride would be an understatement. However, INSY is holding up over the $4 level and is right at downtrend resistance. A push higher to $5 would be encouraging, even if this level acts as resistance on its first attempt. But a break below $4 -- especially in the near-term -- would be worrisome and puts the lows back on the table. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 7 Pharmaceutical Stocks That Just Raised Prices This Year appeared first on InvestorPlace.
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
Democrats take on drug prices. Will a drug pricing battle hurt biotech? With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Karen Finerman and Dan Nathan.
U.S. stocks came under pressure amid signals of a widening trade deficit with China and trepidation over the start of corporate earnings season.